Commentary: Surgical standardization in mesothelioma trials

Our plain-English summary of Commentary: Surgical standardization in mesothelioma trials, by V.W. Rusch (The Journal of Thoracic and Cardiovascular Surgery, 2022).

The study

• Author: V.W. Rusch
• Journal: The Journal of Thoracic and Cardiovascular Surgery
• Published: 2022;163(6):1949-1950
• Type of article: Editorial, Comment
• Read it: PubMed · Publisher

In plain English

This is a short commentary, not a research study, and it reports no new data. The author discussed a separate article by Hasegawa and colleagues describing a small, multicenter, single-arm Phase II trial of chemotherapy given before surgery in selected patients with malignant pleural mesothelioma. The commentary gives no numerical results from that trial and does not discuss asbestos exposure. The author wrote that the trial corroborated earlier trials showing this approach was feasible. As background, the author explained that surgeons had shifted toward lung-sparing operations, which vary more in extent than extrapleural pneumonectomy. An international committee is developing more detailed terms to describe these operations. The author highlighted the trial's methods: guidelines and educational sessions for participating surgeons, surgical videos to check how much was removed, an internationally accepted system for recording complications, and macroscopic complete resection as the main endpoint. The author concluded that, although the trial was small, its results were high quality and it set a high bar for surgical trial design in mesothelioma.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Commentary (expert opinion) on another published clinical trial; no original data
• Who was studied: No population was studied in this commentary. It discusses a separate small, multicenter, single-arm Phase II trial by Hasegawa and colleagues in selected patients with malignant pleural mesothelioma. The commentary does not give patient numbers, locations or dates.
• Exposure: Not applicable. The commentary does not discuss asbestos or any other exposure. The trial it discusses tested chemotherapy before surgery (neoadjuvant chemotherapy followed by surgical resection).
• Main results:
  • The author wrote that the Hasegawa trial corroborated earlier trials of similar design that showed preoperative chemotherapy followed by surgery was feasible.
  • As background, citing earlier studies, the author stated that thoracic surgeons shifted to lung-sparing operations (P/D or EPD).
  • The author reported that the IASLC mesothelioma subcommittee is developing a more detailed system of terms for describing how much was removed in lung-sparing operations.
  • The author described the trial as giving participating surgeons detailed operative descriptions and educational sessions as guidelines.
  • The author described the trial as using surgical videos to verify the extent of resection.
  • The author described the trial as using macroscopic complete resection (MCR) as its primary endpoint.
• The authors' conclusion: The author concluded that, although the Hasegawa trial was small, its results were high quality, and that it set a high bar for surgical trial design in malignant pleural mesothelioma.
• Limitations the authors state:
  • The author noted that the trial under discussion was small.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Medical terms in this study, explained in our Lexicon: Mesothelioma.

Related studies

• Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting — R.R. Gill, A.S. Tsao, et al. (2019)
• Pathologic Considerations and Standardization in Mesothelioma Clinical Trials — M.S. Tsao, M. Carbone, et al. (2019)
• Progress of research on microRNAs with diagnostic value in asbestos exposure: A call for method standardization — L. Micolucci, M.R. Rippo, et al. (2017)
• Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial — A.O. Clive, H. Taylor, et al. (2016)
• Commentary: the 1968 BOHS Chrysotile Asbestos Standard — T.L. Ogden, British Occupational Hygiene Society (2003)
• Surgery and mesothelioma: if not randomization, at least standardization and registration! — H. Pass (2011)

Browse more research in The Journal of Thoracic and Cardiovascular Surgery, or return to medical research.